FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:847-858 August 28, 2003 Number 9 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Avery, R. K. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant.

Methods A total of 634 patients were randomly assigned to receive 1.5 mg of everolimus per day (209 patients), 3.0 mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kilogram of body weight per day (214 patients), in combination with cyclosporine, corticosteroids, and statins. The primary efficacy end point was a composite of death, graft loss or retransplantation, loss to follow-up, biopsy-proved acute rejection of grade 3A, or rejection with hemodynamic compromise.

Results At six months, the percentage of patients who had reached the primary efficacy end point was significantly smaller in the group given 3.0 mg of everolimus (27.0 percent, P<0.001) and the group given 1.5 mg of everolimus (36.4 percent, P=0.03) than in the azathioprine group (46.7 percent). Intravascular ultrasonography showed that the average increase in maximal intimal thickness 12 months after transplantation was significantly smaller in the two everolimus groups than in the azathioprine group. The incidence of vasculopathy was also significantly lower in the 1.5-mg group (35.7 percent, P=0.045) and the 3.0-mg group (30.4 percent, P=0.01) than in the azathioprine group (52.8 percent). The rates of cytomegalovirus infection were significantly lower in the 1.5-mg group (7.7 percent, P<0.001) and the 3.0-mg group (7.6 percent, P<0.001) than in the azathioprine group (21.5 percent). Rates of bacterial infection were significantly higher in the 3.0-mg group than in the azathioprine group. Serum creatinine levels were also significantly higher in the two everolimus groups than in the azathioprine group.

Conclusions Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.

Source Information

From Temple University, Philadelphia (H.J.E.); the Cleveland Clinic Foundation, Cleveland (E.M.T., R.C.S.); Hôpital La Pitié–Salpêtrière, Paris (R.D.); the University of California at Los Angeles, Los Angeles (J.K.); Columbia Presbyterian Medical Center, New York (D.M.); Stanford University School of Medicine, Stanford, Calif. (H.A.V.-K.); Skejby University Hospital, Aarhus, Denmark (K.S.); Deutsches Herzzentrum, Berlin, Germany (M.H.); Novartis Pharmaceuticals, Summit, N.J. (J.M.L.); and Novartis Pharma, Basel, Switzerland (K.H.A., P.B.).

Address reprint requests to Dr. Eisen at the Section of Cardiology, Temple University School of Medicine, 3401 N. Broad St., Philadelphia, PA 19140, or at eisenh{at}tuhs.temple.edu.

Full Text of this Article

Related Letters:

Everolimus in Cardiac-Transplant Recipients
Banas B., Böger C., Krämer B., Eisen H. J., the RAD B253 Study Group
Extract | Full Text | PDF  
N Engl J Med 2003; 349:2271-2272, Dec 4, 2003. Correspondence

This article has been cited by other articles:

• Onuma, Y., Serruys, P. W., Kukreja, N., Veldhof, S., Doostzadeh, J., Cao, S., Stone, G. W., on behalf of the SPIRIT II and III Investigators, (2010). Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur Heart J : ehp599v1-ehp599 [Abstract] [Full Text]  
• Okamoto, I., Doi, T., Ohtsu, A., Miyazaki, M., Tsuya, A., Kurei, K., Kobayashi, K., Nakagawa, K. (2010). Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors. Jpn J Clin Oncol 40: 17-23 [Abstract] [Full Text]  
• Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., Vigneri, R. (2009). Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123 [Abstract] [Full Text]  
• Bhama, J. K., Nguyen, D. Q., Scolieri, S., Teuteberg, J. J., Toyoda, Y., Kormos, R. L., McCurry, K. R., McNamara, D., Bermudez, C. A. (2009). Surgical revascularization for cardiac allograft vasculopathy: Is it still an option?. J. Thorac. Cardiovasc. Surg. 137: 1488-1492 [Abstract] [Full Text]  
• Raichlin, E., Prasad, A., Kremers, W. K., Edwards, B. S., Rihal, C. S., Lerman, A., Kushwaha, S. S. (2009). Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients. Eur Heart J 30: 1356-1363 [Abstract] [Full Text]  
• Delmonte, A., Ghielmini, M., Sessa, C. (2009). Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas. The Oncologist 14: 511-525 [Abstract] [Full Text]  
• Baetta, R., Granata, A., Canavesi, M., Ferri, N., Arnaboldi, L., Bellosta, S., Pfister, P., Corsini, A. (2009). Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits. J. Pharmacol. Exp. Ther. 328: 419-425 [Abstract] [Full Text]  
• Hegner, B., Lange, M., Kusch, A., Essin, K., Sezer, O., Schulze-Lohoff, E., Luft, F. C., Gollasch, M., Dragun, D. (2009). mTOR Regulates Vascular Smooth Muscle Cell Differentiation From Human Bone Marrow-Derived Mesenchymal Progenitors. Arterioscler. Thromb. Vasc. Bio. 29: 232-238 [Abstract] [Full Text]  
• Schwarz, J. B.K., Langwieser, N., Langwieser, N. N., Bek, M. J., Seidl, S., Eckstein, H.-H., Lu, B., Schomig, A., Pavenstadt, H., Zohlnhofer, D. (2009). Novel Role of the CXC Chemokine Receptor 3 in Inflammatory Response to Arterial Injury: Involvement of mTORC1. Circ. Res. 104: 189-200 [Abstract] [Full Text]  
• Crespo-Leiro, M. G., Hermida-Prieto, M. (2008). Sirolimus treatment of left ventricular hypertrophy: who, and when?. Eur Heart J 29: 2703-2704 [Full Text]  
• Seron, D., Arns, W., Chapman, J. R. (2008). Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies. Nephrol Dial Transplant 23: 2467-2473 [Full Text]  
• Bruyn, G A W, Tate, G, Caeiro, F, Maldonado-Cocco, J, Westhovens, R, Tannenbaum, H, Bell, M, Forre, O, Bjorneboe, O, Tak, P P, Abeywickrama, K H, Bernhardt, P, van Riel, P L C, for the RADD study group, (2008). Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann Rheum Dis 67: 1090-1095 [Abstract] [Full Text]  
• Stone, G. W., Midei, M., Newman, W., Sanz, M., Hermiller, J. B., Williams, J., Farhat, N., Mahaffey, K. W., Cutlip, D. E., Fitzgerald, P. J., Sood, P., Su, X., Lansky, A. J., for the SPIRIT III Investigators, (2008). Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial. JAMA 299: 1903-1913 [Abstract] [Full Text]  
• Schmauss, D., Weis, M. (2008). Cardiac Allograft Vasculopathy: Recent Developments. Circulation 117: 2131-2141 [Abstract] [Full Text]  
• O'Donnell, A., Faivre, S., Burris, H. A. III, Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., Brock, C., Jones, S., Raymond, E., Judson, I. (2008). Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors. JCO 26: 1588-1595 [Abstract] [Full Text]  
• Sulemanjee, N. Z., Merla, R., Lick, S. D., Aunon, S. M., Taylor, M., Manson, M., Czer, L. S.C., Schwarz, E. R. (2008). The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications. J CARDIOVASC PHARMACOL THER 13: 13-31 [Abstract]  
• van de Beek, D., Kremers, W. K., Del Pozo, J. L., Daly, R. C., Edwards, B. S., McGregor, C. G. A., Patel, R. (2008). Effect of Infectious Diseases on Outcome After Heart Transplant. Mayo Clin Proc. 83: 304-308 [Abstract] [Full Text]  
• Nwakanma, L. U., Shah, A. S., Conte, J. V., Baumgartner, W. A. (2008). Heart Transplantation. Card Surg Adult 3: 1539-1578 [Full Text]  
• Mudge, G. H. Jr (2007). Sirolimus and Cardiac Transplantation: Is It the "Magic Bullet"?. Circulation 116: 2666-2668 [Full Text]  
• Raichlin, E., Bae, J.-H., Khalpey, Z., Edwards, B. S., Kremers, W. K., Clavell, A. L., Rodeheffer, R. J., Frantz, R. P., Rihal, C., Lerman, A., Kushwaha, S. S. (2007). Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. Circulation 116: 2726-2733 [Abstract] [Full Text]  
• Rose, M. L. (2007). Interferon-{gamma} and Intimal Hyperplasia. Circ. Res. 101: 542-544 [Full Text]  
• Wang, Y., Bai, Y., Qin, L., Zhang, P., Yi, T., Teesdale, S. A., Zhao, L., Pober, J. S., Tellides, G. (2007). Interferon-{gamma} Induces Human Vascular Smooth Muscle Cell Proliferation and Intimal Expansion by Phosphatidylinositol 3-Kinase Dependent Mammalian Target of Rapamycin Raptor Complex 1 Activation. Circ. Res. 101: 560-569 [Abstract] [Full Text]  
• Gambino, A., Cerutti, A., Feltrin, G., Toscano, G., Tarantini, G., Milanesi, O., Angelini, A., Gerosa, G. (2007). Outcome after pediatric heart transplantation: two decades of a single center experience. Eur. J. Cardiothorac. Surg. 32: 220-224 [Abstract] [Full Text]  
• Pascual, J., Galeano, C., Celemin, D., Alarcon, M. C., Marcen, R., Fernandez, A. M., Burgos, F. J., Ortuno, J. (2007). Uneventful Thoracic Healing With Everolimus After Aortic Valve Replacement. Ann. Thorac. Surg. 84: 271-272 [Abstract] [Full Text]  
• Tellides, G., Pober, J. S. (2007). Interferon-{gamma} Axis in Graft Arteriosclerosis. Circ. Res. 100: 622-632 [Abstract] [Full Text]  
• Eilers, E., Moter, A., Bollmann, R., Haffner, D., Querfeld, U. (2007). Intrarenal Abscesses Due to Ureaplasma urealyticum in a Transplanted Kidney. J. Clin. Microbiol. 45: 1066-1068 [Abstract] [Full Text]  
• Andrews, J., Mason, J. C. (2007). Takayasu's arteritis--recent advances in imaging offer promise. Rheumatology (Oxford) 46: 6-15 [Abstract] [Full Text]  
• Krotz, F., Keller, M., Derflinger, S., Schmid, H., Gloe, T., Bassermann, F., Duyster, J., Cohen, C. D., Schuhmann, C., Klauss, V., Pohl, U., Stempfle, H.-U., Sohn, H.-Y. (2007). Mycophenolate Acid Inhibits Endothelial NAD(P)H Oxidase Activity and Superoxide Formation by a Rac1-Dependent Mechanism. Hypertension 49: 201-208 [Abstract] [Full Text]  
• Tu, W., Potena, L., Stepick-Biek, P., Liu, L., Dionis, K. Y., Luikart, H., Fearon, W. F., Holmes, T. H., Chin, C., Cooke, J. P., Valantine, H. A., Mocarski, E. S., Lewis, D. B. (2006). T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease. Circulation 114: 1608-1615 [Abstract] [Full Text]  
• Ford, K. A (2006). Paediatric immunosuppression following solid organ transplantation. EDUCATION AND PRACTICE 91: ep87-ep91 [Full Text]  
• Yee, K. W.L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., O'Brien, S., Andreeff, M., Giles, F. J. (2006). Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies. Clin. Cancer Res. 12: 5165-5173 [Abstract] [Full Text]  
• Kobashigawa, J. A. (2006). Cardiac Allograft Vasculopathy in Heart Transplant Patients: Pathologic and Clinical Aspects for Angioplasty/Stenting. J Am Coll Cardiol 48: 462-463 [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Schoenhagen, P., Nissen, S. E. (2006). Intravascular Ultrasound in Cardiovascular Medicine. Circulation 114: e55-e59 [Full Text]  
• Tona, F., Caforio, A. L.P., Montisci, R., Gambino, A., Angelini, A., Ruscazio, M., Toscano, G., Feltrin, G., Ramondo, A., Gerosa, G., Iliceto, S. (2006). Coronary Flow Velocity Pattern and Coronary Flow Reserve by Contrast-Enhanced Transthoracic Echocardiography Predict Long-Term Outcome in Heart Transplantation. Circulation 114: I-49-I-55 [Abstract] [Full Text]  
• Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., Schoenhagen, P., Crowe, T., Cain, V., Wolski, K., Goormastic, M., Tuzcu, E. M., for the ASTEROID Investigators, (2006). Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA 295: 1556-1565 [Abstract] [Full Text]  
• Hoffman, F. M., Nelson, B. J., Drangstveit, M. B., Flynn, B. M., Watercott, E. A., Zirbes, J. M. (2006). Caring for Transplant Recipients in a Nontransplant Setting. Crit Care Nurse 26: 53-73 [Full Text]  
• Nissen, S. E., Tuzcu, E. M., Brewer, H. B., Sipahi, I., Nicholls, S. J., Ganz, P., Schoenhagen, P., Waters, D. D., Pepine, C. J., Crowe, T. D., Davidson, M. H., Deanfield, J. E., Wisniewski, L. M., Hanyok, J. J., Kassalow, L. M., the ACAT Intravascular Atherosclerosis Treatment, (2006). Effect of ACAT inhibition on the progression of coronary atherosclerosis.. NEJM 354: 1253-1263 [Abstract] [Full Text]  
• Schomig, A., Kastrati, A., Wessely, R. (2005). Prevention of Restenosis by Systemic Drug Therapy: Back to the Future?. Circulation 112: 2759-2761 [Full Text]  
• Koshman, S. L, Lalonde, L. D, Burton, I., Tymchak, W. J, Pearson, G. J (2005). Supratherapeutic Response to Ezetimibe Administered with Cyclosporine. The Annals of Pharmacotherapy 39: 1561-1565 [Abstract] [Full Text]  
• Hosenpud, J. D. (2005). Immunosuppression in Cardiac Transplantation. NEJM 352: 2749-2750 [Full Text]  
• Romeo, G., Houyel, L., Angel, C.-Y., Brenot, P., Riou, J.-Y., Paul, J.-F. (2005). Coronary Stenosis Detection by 16-Slice Computed Tomography in Heart Transplant Patients: Comparison With Conventional Angiography and Impact on Clinical Management. J Am Coll Cardiol 45: 1826-1831 [Abstract] [Full Text]  
• Alfonso, F, Moreno, R, Vergas, J (2005). Fatal infection after rapamycin eluting coronary stent implantation. Heart 91: e51-e51 [Abstract] [Full Text]  
• Tuzcu, E. M., Kapadia, S. R., Sachar, R., Ziada, K. M., Crowe, T. D., Feng, J., Magyar, W. A., Hobbs, R. E., Starling, R. C., Young, J. B., McCarthy, P., Nissen, S. E. (2005). Intravascular Ultrasound Evidence of Angiographically Silent Progression in Coronary Atherosclerosis Predicts Long-Term Morbidity and Mortality After Cardiac Transplantation. J Am Coll Cardiol 45: 1538-1542 [Abstract] [Full Text]  
• Razonable, R. R. (2005). Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 62: S7-S13 [Abstract] [Full Text]  
• Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., Ganz, P., the Reversal of Atherosclerosis with Aggressive Li, (2005). Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. NEJM 352: 29-38 [Abstract] [Full Text]  
• Lindenfeld, J., Page, R. L. II, Zolty, R., Shakar, S. F., Levi, M., Lowes, B., Wolfel, E. E., Miller, G. G. (2005). Drug Therapy in the Heart Transplant Recipient: Part III: Common Medical Problems. Circulation 111: 113-117 [Full Text]  
• Marti, H.-P., Frey, F. J. (2005). Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 20: 13-15 [Full Text]  
• Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P., Lane, H. A., Reardon, D. A., Cavenee, W. K., Wang, X.-F., Bigner, D. D., Friedman, H. S., Rich, J. N. (2005). Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics 4: 101-112 [Abstract] [Full Text]  
• Halloran, P. F. (2004). Immunosuppressive Drugs for Kidney Transplantation. NEJM 351: 2715-2729 [Full Text]  
• Lindenfeld, J., Miller, G. G., Shakar, S. F., Zolty, R., Lowes, B. D., Wolfel, E. E., Mestroni, L., Page, R. L. II, Kobashigawa, J. (2004). Drug Therapy in the Heart Transplant Recipient: Part II: Immunosuppressive Drugs. Circulation 110: 3858-3865 [Full Text]  
• Keogh, A., Richardson, M., Ruygrok, P., Spratt, P., Galbraith, A., O'Driscoll, G., Macdonald, P., Esmore, D., Muller, D., Faddy, S. (2004). Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years: A Randomized Clinical Trial. Circulation 110: 2694-2700 [Abstract] [Full Text]  
• Offman, J., Opelz, G., Doehler, B., Cummins, D., Halil, O., Banner, N. R., Burke, M. M., Sullivan, D., Macpherson, P., Karran, P. (2004). Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104: 822-828 [Abstract] [Full Text]  
• Grube, E., Sonoda, S., Ikeno, F., Honda, Y., Kar, S., Chan, C., Gerckens, U., Lansky, A. J., Fitzgerald, P. J. (2004). Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer. Circulation 109: 2168-2171 [Abstract] [Full Text]  
• Eisen, H. J. (2004). Adverse outcomes from the use of older donor hearts in cardiac transplant recipients: The pros and cons of expanded donor criteria. J Am Coll Cardiol 43: 1562-1564 [Full Text]  
• Kreis, H., Oberbauer, R., Campistol, J. M., Mathew, T., Daloze, P., Schena, F. P., Burke, J. T., Brault, Y., Gioud-Paquet, M., Scarola, J. A., Neylan, J. F. (2004). Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine Withdrawal. J. Am. Soc. Nephrol. 15: 809-817 [Abstract] [Full Text]  
• (2003). Preventing Allograft Rejection After Transplant. Journal Watch Cardiology 2003: 4-4 [Full Text]  
• Banas, B., Boger, C., Kramer, B., Eisen, H. J., the RAD B253 Study Group, (2003). Everolimus in Cardiac-Transplant Recipients. NEJM 349: 2271-2272 [Full Text]  
• Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., Halpern, S., Crowe, T., Blankenship, J. C., Kerensky, R. (2003). Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial. JAMA 290: 2292-2300 [Abstract] [Full Text]  
• SoRelle, R. (2003). Cardiovascular News. Circulation 108 : e9016-e9017 [Full Text]